Cantor Fitzgerald Boosts ADMA Biologics (NASDAQ:ADMA) Price Target to $10.00

ADMA Biologics (NASDAQ:ADMA) had its target price lifted by equities researchers at Cantor Fitzgerald from $8.00 to $10.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 14.03% from the stock’s previous close.

A number of other research analysts have also recently issued reports on ADMA. Mizuho boosted their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright lifted their target price on ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $9.50.

ADMA Biologics Stock Performance

ADMA Biologics stock traded up $1.84 during trading hours on Friday, reaching $8.77. 6,892,022 shares of the company were exchanged, compared to its average volume of 2,629,903. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -67.46 and a beta of 0.43. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04. The stock has a 50-day moving average of $6.33 and a 200 day moving average of $5.09. ADMA Biologics has a 12 month low of $3.06 and a 12 month high of $8.84.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The business had revenue of $81.90 million during the quarter, compared to analyst estimates of $77.28 million. During the same period in the prior year, the company posted ($0.03) earnings per share. ADMA Biologics’s revenue was up 43.9% on a year-over-year basis. As a group, research analysts anticipate that ADMA Biologics will post 0.3 earnings per share for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $6.01, for a total value of $299,820.87. Following the sale, the director now owns 2,527,500 shares in the company, valued at approximately $15,190,275. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 639,895 shares of company stock worth $3,927,169 in the last 90 days. Insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently modified their holdings of ADMA. ProShare Advisors LLC grew its holdings in shares of ADMA Biologics by 9.2% in the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 4,570 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares during the period. Inspire Investing LLC lifted its stake in ADMA Biologics by 125.2% during the first quarter. Inspire Investing LLC now owns 189,303 shares of the biotechnology company’s stock worth $1,249,000 after purchasing an additional 105,256 shares during the last quarter. Sei Investments Co. lifted its stake in ADMA Biologics by 176.0% during the first quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock worth $2,597,000 after purchasing an additional 250,925 shares during the last quarter. Finally, ClariVest Asset Management LLC lifted its stake in shares of ADMA Biologics by 186.2% in the 1st quarter. ClariVest Asset Management LLC now owns 569,225 shares of the biotechnology company’s stock valued at $3,757,000 after acquiring an additional 370,319 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.